Carla M. van Herpen

Pharmacogenetic Screening of CYP3A and ABCB1 in Relation to Population Pharmacokinetics of Docetaxel

Tessa M. Bosch, Alwin D. R. Huitema, Valerie D. Doodeman et al. · Clinical Cancer Research · 2006 · 125 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Tumor volume as prognostic factor in chemoradiation for advanced head and neck cancer

J. Knegjens, Michael Hauptmann, Frank A. Pameijer et al. · Head & Neck · 2010 · 103 citations

Medicine, Oncology, Radiation Oncology +12

Intratumoral Administration of Recombinant Human Interleukin 12 in Head and Neck Squamous Cell Carcinoma Patients Elicits a T-Helper 1 Profile in the Locoregional Lymph Nodes

Carla M. van Herpen, Maaike W.G. Looman, Marijke I. Zonneveld et al. · Clinical Cancer Research · 2004 · 88 citations · Full text

Life Sciences, Immunology, Oncology +17

Experimental treatment of NRAS-mutated neurocutaneous melanocytosis with MEK162, a MEK-inhibitor

Heidi V.N. Küsters‐Vandevelde, Annelieke E.C.A.B. Willemsen, Patricia J.T.A. Groenen et al. · Acta Neuropathologica Communications · 2014 · 62 citations · Full text

Medicine, Dermatology, Oncology +17

Pharmacokinetics and immunological aspects of a phase Ib study with intratumoral administration of recombinant human interleukin-12 in patients with head and neck squamous cell carcinoma: a decrease of T-bet in peripheral blood mononuclear cells.

Carla M. van Herpen, Richard Huijbens, Maaike W.G. Looman et al. · PubMed · 2003 · 50 citations

Medicine, Immunology, Pharmacology +17